A joint industry‐sponsored data monitoring committee model for observational, retrospective drug safety studies in the real‐world setting
暂无分享,去创建一个
A. Neugut | J. Massaro | J. Sosa | A. Hollenberg | O. Adetunji | A. Major-Pedersen | Mary Kate McCullen | M. Sabol | A. Major‐Pedersen
[1] H. Howe. North American Association of Central Cancer Registries , 2020, Definitions.
[2] Jonathan H Seltzer,et al. The changing landscape of data monitoring committees—Perspectives from regulators, members, and sponsors , 2018, Biometrical journal. Biometrische Zeitschrift.
[3] D. DeMets,et al. Data Monitoring Committees: Current issues , 2018, Clinical trials.
[4] D. DeMets,et al. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative , 2017, Clinical trials.
[5] L. Lund,et al. Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions , 2017, Current Heart Failure Reports.
[6] D. DeMets,et al. Data Monitoring Committees - Expect the Unexpected. , 2016, The New England journal of medicine.
[7] Jonathan H Seltzer,et al. Responsibilities of Data Monitoring Committees: Consensus Recommendations , 2016, Therapeutic innovation & regulatory science.
[8] Daniel L Gillen,et al. Data monitoring committees for pragmatic clinical trials , 2015, Clinical trials.
[9] D. DeMets,et al. Enhancing Trial Integrity by Protecting the Independence of Data Monitoring Committees in Clinical Trials , 2014, Journal of biopharmaceutical statistics.
[10] Christy Chuang-Stein,et al. A Practical Guide to Data Monitoring Committees in Adaptive Trials , 2014, Therapeutic innovation & regulatory science.
[11] A. Carlsson,et al. When is it safe to stop for safety? , 2012, Journal of thrombosis and haemostasis : JTH.
[12] J. Drazen,et al. Don't mess with the DSMB. , 2010, The New England journal of medicine.
[13] D. Cook,et al. Event adjudication and data monitoring in an intensive care unit observational study of thromboprophylaxis. , 2009, Journal of critical care.
[14] D. Moher,et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement , 2008, BMJ : British Medical Journal.
[15] Arthur S Slutsky,et al. A primer on data safety monitoring boards: mission, methods, and controversies , 2007, Intensive Care Medicine.
[16] S. Goodman. Stopping at Nothing? Some Dilemmas of Data Monitoring in Clinical Trials , 2007, Annals of Internal Medicine.
[17] L. Burgio,et al. Data and safety monitoring in social behavioral intervention trials: the REACH II experience , 2006, Clinical trials.
[18] Sydes,et al. A proposed charter for clinical trial data monitoring committees: helping them to do their job well , 2005, The Lancet.
[19] D. Lilienfeld. Pharmacoepidemiology 101: data monitoring committees in the post‐marketing approval setting , 2004, Pharmacoepidemiology and drug safety.
[20] J. Wittes. Playing safe and preserving integrity: making the FDA model work , 2004, Statistics in medicine.
[21] D. DeMets,et al. Issues in regulatory guidelines for data monitoring committees , 2004, Clinical trials.
[22] D. Spiegelhalter,et al. Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials , 2004, Clinical trials.
[23] D. DeMets,et al. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials. , 1995, Controlled clinical trials.
[24] John B. Watkins,et al. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[25] Guideline on good pharmacovigilance practices ( GVP ) Module , 2013 .
[26] I NHI,et al. Organization, review, and administration of cooperative studies (Greenberg Report): a report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967. , 1988, Controlled clinical trials.
[27] J. Lellouch,et al. Explanatory and pragmatic attitudes in therapeutical trials. , 1967, Journal of chronic diseases.